TR201901745T4 - 19-nor C3,3-disübstitüe edilmiş C21- n-pirazolil steroidleri ve bunların kullanım yöntemleri. - Google Patents

19-nor C3,3-disübstitüe edilmiş C21- n-pirazolil steroidleri ve bunların kullanım yöntemleri. Download PDF

Info

Publication number
TR201901745T4
TR201901745T4 TR2019/01745T TR201901745T TR201901745T4 TR 201901745 T4 TR201901745 T4 TR 201901745T4 TR 2019/01745 T TR2019/01745 T TR 2019/01745T TR 201901745 T TR201901745 T TR 201901745T TR 201901745 T4 TR201901745 T4 TR 201901745T4
Authority
TR
Turkey
Prior art keywords
substituted
applications
unsubstituted
compound
alkyl
Prior art date
Application number
TR2019/01745T
Other languages
English (en)
Turkish (tr)
Inventor
Martinez Botella Gabriel
L Harrison Boyd
Jean Robichaud Albert
G Salituro Francesco
Thomas Beresis Richard
Original Assignee
Sage Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sage Therapeutics Inc filed Critical Sage Therapeutics Inc
Publication of TR201901745T4 publication Critical patent/TR201901745T4/tr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/58—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A61K31/573—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/16—Otologicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J15/00—Stereochemically pure steroids containing carbon, hydrogen, halogen or oxygen having a partially or totally inverted skeleton, e.g. retrosteroids, L-isomers
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J3/00—Normal steroids containing carbon, hydrogen, halogen or oxygen, substituted in position 17 beta by one carbon atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J43/00—Normal steroids having a nitrogen-containing hetero ring spiro-condensed or not condensed with the cyclopenta(a)hydrophenanthrene skeleton
    • C07J43/003—Normal steroids having a nitrogen-containing hetero ring spiro-condensed or not condensed with the cyclopenta(a)hydrophenanthrene skeleton not condensed
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J5/00—Normal steroids containing carbon, hydrogen, halogen or oxygen, substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane and substituted in position 21 by only one singly bound oxygen atom, i.e. only one oxygen bound to position 21 by a single bond
    • C07J5/0046—Normal steroids containing carbon, hydrogen, halogen or oxygen, substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane and substituted in position 21 by only one singly bound oxygen atom, i.e. only one oxygen bound to position 21 by a single bond substituted in position 17 alfa
    • C07J5/0053—Normal steroids containing carbon, hydrogen, halogen or oxygen, substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane and substituted in position 21 by only one singly bound oxygen atom, i.e. only one oxygen bound to position 21 by a single bond substituted in position 17 alfa not substituted in position 16
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J7/00—Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of two carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J1/00—Normal steroids containing carbon, hydrogen, halogen or oxygen, not substituted in position 17 beta by a carbon atom, e.g. estrane, androstane
    • C07J1/0051—Estrane derivatives
    • C07J1/0059—Estrane derivatives substituted in position 17 by a keto group
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J1/00—Normal steroids containing carbon, hydrogen, halogen or oxygen, not substituted in position 17 beta by a carbon atom, e.g. estrane, androstane
    • C07J1/0051—Estrane derivatives
    • C07J1/0066—Estrane derivatives substituted in position 17 beta not substituted in position 17 alfa
    • C07J1/007—Estrane derivatives substituted in position 17 beta not substituted in position 17 alfa the substituent being an OH group free esterified or etherified
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J1/00—Normal steroids containing carbon, hydrogen, halogen or oxygen, not substituted in position 17 beta by a carbon atom, e.g. estrane, androstane
    • C07J1/0051—Estrane derivatives
    • C07J1/0066—Estrane derivatives substituted in position 17 beta not substituted in position 17 alfa
    • C07J1/007—Estrane derivatives substituted in position 17 beta not substituted in position 17 alfa the substituent being an OH group free esterified or etherified
    • C07J1/0074—Esters
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J13/00—Normal steroids containing carbon, hydrogen, halogen or oxygen having a carbon-to-carbon double bond from or to position 17
    • C07J13/007—Normal steroids containing carbon, hydrogen, halogen or oxygen having a carbon-to-carbon double bond from or to position 17 with double bond in position 17 (20)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J21/00—Normal steroids containing carbon, hydrogen, halogen or oxygen having an oxygen-containing hetero ring spiro-condensed with the cyclopenta(a)hydrophenanthrene skeleton
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J31/00—Normal steroids containing one or more sulfur atoms not belonging to a hetero ring
    • C07J31/006—Normal steroids containing one or more sulfur atoms not belonging to a hetero ring not covered by C07J31/003
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J5/00—Normal steroids containing carbon, hydrogen, halogen or oxygen, substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane and substituted in position 21 by only one singly bound oxygen atom, i.e. only one oxygen bound to position 21 by a single bond
    • C07J5/0007—Normal steroids containing carbon, hydrogen, halogen or oxygen, substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane and substituted in position 21 by only one singly bound oxygen atom, i.e. only one oxygen bound to position 21 by a single bond not substituted in position 17 alfa
    • C07J5/0015—Normal steroids containing carbon, hydrogen, halogen or oxygen, substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane and substituted in position 21 by only one singly bound oxygen atom, i.e. only one oxygen bound to position 21 by a single bond not substituted in position 17 alfa not substituted in position 16
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J7/00—Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of two carbon atoms
    • C07J7/0005—Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of two carbon atoms not substituted in position 21
    • C07J7/001—Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of two carbon atoms not substituted in position 21 substituted in position 20 by a keto group
    • C07J7/0015—Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of two carbon atoms not substituted in position 21 substituted in position 20 by a keto group not substituted in position 17 alfa
    • C07J7/002—Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of two carbon atoms not substituted in position 21 substituted in position 20 by a keto group not substituted in position 17 alfa not substituted in position 16
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J7/00—Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of two carbon atoms
    • C07J7/0005—Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of two carbon atoms not substituted in position 21
    • C07J7/0065—Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of two carbon atoms not substituted in position 21 substituted in position 20 by an OH group free esterified or etherified
    • C07J7/007—Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of two carbon atoms not substituted in position 21 substituted in position 20 by an OH group free esterified or etherified not substituted in position 17 alfa
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J7/00—Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of two carbon atoms
    • C07J7/008—Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of two carbon atoms substituted in position 21
    • C07J7/0085—Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of two carbon atoms substituted in position 21 by an halogen atom

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Epidemiology (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Addiction (AREA)
  • Hospice & Palliative Care (AREA)
  • Anesthesiology (AREA)
  • Psychology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Dermatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Steroid Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
TR2019/01745T 2013-04-17 2014-04-17 19-nor C3,3-disübstitüe edilmiş C21- n-pirazolil steroidleri ve bunların kullanım yöntemleri. TR201901745T4 (tr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
CN2013074323 2013-04-17

Publications (1)

Publication Number Publication Date
TR201901745T4 true TR201901745T4 (tr) 2019-03-21

Family

ID=51730809

Family Applications (1)

Application Number Title Priority Date Filing Date
TR2019/01745T TR201901745T4 (tr) 2013-04-17 2014-04-17 19-nor C3,3-disübstitüe edilmiş C21- n-pirazolil steroidleri ve bunların kullanım yöntemleri.

Country Status (26)

Country Link
US (6) US9512165B2 (enExample)
EP (4) EP3909966B1 (enExample)
JP (7) JP6470258B2 (enExample)
KR (4) KR102239541B1 (enExample)
CN (4) CN113527400B (enExample)
AU (5) AU2014256229B2 (enExample)
BR (1) BR112015026380A8 (enExample)
CA (1) CA2909545A1 (enExample)
CY (2) CY1121228T1 (enExample)
DK (3) DK3909966T3 (enExample)
ES (3) ES2886182T3 (enExample)
HR (2) HRP20190232T1 (enExample)
HU (2) HUE041369T2 (enExample)
IL (4) IL286794B2 (enExample)
LT (2) LT3498725T (enExample)
MX (3) MX362543B (enExample)
PL (2) PL3498725T3 (enExample)
PT (2) PT3498725T (enExample)
RS (2) RS58297B1 (enExample)
RU (1) RU2675855C2 (enExample)
SG (2) SG10201802389SA (enExample)
SI (2) SI2986623T1 (enExample)
SM (2) SMT201900066T1 (enExample)
TR (1) TR201901745T4 (enExample)
WO (1) WO2014169833A1 (enExample)
ZA (1) ZA201507740B (enExample)

Families Citing this family (72)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101583620B (zh) 2005-11-28 2016-08-17 马里纳斯医药公司 加奈索酮组合物及其制备和使用方法
AU2012323888A1 (en) 2011-10-14 2014-05-29 Sage Therapeutics, Inc. 3,3 disubstituted 19-nor pregnane compounds, compositions, and uses thereof
NZ627781A (en) 2012-01-23 2016-10-28 Sage Therapeutics Inc Neuroactive steroid formulations and methods of treating cns disorders
WO2013139861A1 (en) 2012-03-20 2013-09-26 Luc Montagnier Methods and pharmaceutical compositions of the treatment of autistic syndrome disorders
SG10201608148TA (en) 2012-08-21 2016-11-29 Sage Therapeutics Inc Methods Of Treating Epilepsy Or Status Epilepticus
DK2986624T3 (da) 2013-04-17 2020-06-29 Sage Therapeutics Inc Neuroaktive 19-nor-steroider til terapeutisk anvendelse
US9725481B2 (en) 2013-04-17 2017-08-08 Sage Therapeutics, Inc. 19-nor C3, 3-disubstituted C21-C-bound heteroaryl steroids and methods of use thereof
US20160068563A1 (en) 2013-04-17 2016-03-10 Boyd L. Harrison 19-nor neuroactive steroids and methods of use thereof
PL3498725T3 (pl) 2013-04-17 2021-11-08 Sage Therapeutics, Inc. 19-Nor C3,3-dipodstawiony C21-N-pirazolilo-steroid do zastosowania w terapii
EP3021852B1 (en) 2013-07-19 2021-01-27 Sage Therapeutics, Inc. Neuroactive steroids, compositions, and uses thereof
PT3488852T (pt) 2013-08-23 2021-02-03 Sage Therapeutics Inc Esteroides neuroativos, composições e seus usos
US10246482B2 (en) 2014-06-18 2019-04-02 Sage Therapeutics, Inc. Neuroactive steroids, compositions, and uses thereof
JOP20200195A1 (ar) 2014-09-08 2017-06-16 Sage Therapeutics Inc سترويدات وتركيبات نشطة عصبياً، واستخداماتها
PE20170925A1 (es) 2014-10-16 2017-07-13 Sage Therapeutics Inc Composiciones y metodos para el tratamiento de trastornos del snc
ES2808855T3 (es) 2014-10-16 2021-03-02 Sage Therapeutics Inc Composiciones y métodos para tratar trastornos del SNC
US10774108B2 (en) 2014-11-27 2020-09-15 Sage Therapeutics, Inc. Compositions and methods for treating CNS disorders
CN104558092B (zh) * 2014-12-29 2017-01-18 北京理工大学 一种甾体皂苷化合物及其制备方法和用途
RS61530B1 (sr) 2015-01-26 2021-04-29 Sage Therapeutics Inc Kompozicije i postupci za lečenje poremećaja cns
WO2016134301A2 (en) 2015-02-20 2016-08-25 Sage Therapeutics, Inc. Neuroactive steroids, compositions, and uses thereof
MA45276A (fr) 2015-06-18 2018-04-25 Sage Therapeutics Inc Solutions de stéroïdes neuroactifs et leurs méthodes d'utilisation
CN104910236B (zh) * 2015-06-26 2016-08-17 西北农林科技大学农药研究所 吡唑基甾体衍生物及其制备方法、用途
WO2017066626A1 (en) 2015-10-16 2017-04-20 Marinus Pharmaceuticals, Inc. Injectable neurosteroid formulations containing nanoparticles
TW202400182A (zh) 2016-03-08 2024-01-01 美商賽吉醫療公司 神經活性類固醇，其組合物及用途
CA3279953A1 (en) * 2016-07-11 2025-11-29 Sage Therapeutics, Inc. C7, c12, and c16 substituted neuroactive steroids and their methods of use
EP4302764A3 (en) 2016-07-11 2024-06-26 Sage Therapeutics, Inc. C17, c20, and c21 substituted neuroactive steroids and their methods of use
EP4233861A3 (en) 2016-08-11 2023-10-11 Ovid Therapeutics, Inc. Compositions for treatment of essential tremor
BR112019003637A2 (pt) 2016-08-23 2019-08-06 Sage Therapeutics Inc um esteróide 19-nor c3,3-dissubstituído c21-n-pirazolil cristalino
US10391105B2 (en) 2016-09-09 2019-08-27 Marinus Pharmaceuticals Inc. Methods of treating certain depressive disorders and delirium tremens
EP3612186A1 (en) * 2017-04-18 2020-02-26 Marinus Pharmaceuticals, Inc. Sustained release injectable neurosteroid formulations
IL270962B2 (en) * 2017-06-01 2023-09-01 Sumitomo Chemical Co A heterocyclic compound and a mixture containing it
IL303250A (en) * 2017-09-07 2023-07-01 Sage Therapeutics Inc Neuroactive steroids and their methods of use
US20220110949A1 (en) * 2017-09-14 2022-04-14 Sage Therapeutics, Inc. A 19-nor c3,3-disubstituted c21-n-pyrazolyl steroid and methods of use thereof
US20210228596A1 (en) * 2017-10-12 2021-07-29 Sage Therapeutics, Inc. Method of treating cns disorders with neurosteroids and gabaergic compounds
JP2021505608A (ja) * 2017-12-08 2021-02-18 セージ セラピューティクス， インコーポレイテッド ＣＮＳ障害を処置するためのジュウテリウム化された２１−［４−シアノ−ピラゾール−１−イル］−１９−ノル−プレガン−３．α−オール−２０−オン誘導体
AU2018392093B2 (en) 2017-12-22 2024-02-01 Sage Therapeutics, Inc. Compositions and methods for treating CNS disorders
IL310454A (en) * 2017-12-22 2024-03-01 Sage Therapeutics Inc Compositions and methods for treating cns disorders
EP3737687B1 (en) * 2018-01-12 2025-10-22 Sage Therapeutics, Inc. Aza-, oxa and thia-pregnan-20-one-3.alpha.-ol compounds for use in treating cns disorders
WO2019154257A1 (zh) * 2018-02-11 2019-08-15 江苏豪森药业集团有限公司 一种甾族类衍生物调节剂及其制备方法和应用
MX2020008182A (es) * 2018-02-11 2020-09-22 Jiangsu Hansoh Pharmaceutical Group Co Ltd Reguladores de derivados esteroides, metodo para prepararlos y usos de los mismos.
CA3103421A1 (en) * 2018-06-12 2019-12-19 Sage Therapeutics, Inc. A 19-nor c3,3-disubstituted c21 -n-pyrazolyl steroid and methods of use thereof
CN111040015B (zh) * 2018-10-15 2022-03-18 南京诺瑞特医药科技有限公司 19-去甲-c21取代类固醇衍生物
CN109503694A (zh) * 2018-11-21 2019-03-22 苏州闻天医药科技有限公司 一种新型gabaa受体调节剂及其用途
KR102892974B1 (ko) 2018-12-05 2025-11-28 세이지 테라퓨틱스, 인크. 신경활성 스테로이드 및 이의 사용 방법
US11266662B2 (en) 2018-12-07 2022-03-08 Marinus Pharmaceuticals, Inc. Ganaxolone for use in prophylaxis and treatment of postpartum depression
CA3121636A1 (en) 2018-12-17 2020-06-25 Intra-Cellular Therapies, Inc. Analogs of (3alpha,5alpha)-3-hydroxy-21-(1h-imidazol-1-yl)-3-methoxymethyl)-pregnan-20-one
CN116425819B (zh) * 2019-01-08 2025-10-03 成都康弘药业集团股份有限公司 甾体类化合物、用途及其制备方法
CA3124703C (en) * 2019-01-14 2023-10-17 Beijing Xuanyi Pharmasciences Co., Ltd. Tetrazolone substituted steroids and use thereof
CN111454318A (zh) * 2019-01-20 2020-07-28 浙江易众化工有限公司 抗抑郁药物sage-217的晶型及其制备方法
US12122804B2 (en) 2019-01-31 2024-10-22 Shenzhen Rentai Pharmatech Ltd. γ-aminobutyric acid modulator crystal form X, preparation method and application thereof
KR20220006565A (ko) 2019-05-10 2022-01-17 브리 바이오사이언시스, 인크. 브렉사놀론, 가낙솔론, 또는 주라놀론을 함유하는 약제 조성물, 및 이것의 용도
WO2020242772A1 (en) 2019-05-28 2020-12-03 Teva Czech Industries S.R.O Solid state forms of sage-217 and processes for preparation thereof
BR112021024033A2 (pt) * 2019-05-31 2022-02-08 Sage Therapeutics Inc Esteroides neuroativos e suas composições
TWI896547B (zh) * 2019-06-27 2025-09-11 美商賽吉醫療公司 用於治療cns病症之組合物及方法
TWI896548B (zh) 2019-06-27 2025-09-11 美商賽吉醫療公司 用於治療cns病症之組合物及方法
EP3990467A1 (en) * 2019-06-27 2022-05-04 Sage Therapeutics, Inc. Compositions and methods for treating cns disorders
WO2021026124A1 (en) 2019-08-05 2021-02-11 Marinus Pharmaceuticals, Inc. Ganaxolone for use in treatment of status epilepticus
WO2021023213A1 (zh) * 2019-08-07 2021-02-11 上海翰森生物医药科技有限公司 一种甾族类衍生物调节剂的盐及其晶型
KR20220103707A (ko) * 2019-09-30 2022-07-22 엘리엄 테라퓨틱스 (유케이) 엘티디 Gabaa 수용체의 아형을 우선적으로 강화시키는 조성물 및 그의 사용 방법
US10857163B1 (en) 2019-09-30 2020-12-08 Athenen Therapeutics, Inc. Compositions that preferentially potentiate subtypes of GABAA receptors and methods of use thereof
AU2020395246A1 (en) * 2019-12-05 2022-06-16 Sage Therapeutics, Inc. A 19-nor C3,3-disubstituted C21-N-pyrazolyl steroid and methods of use thereof
CN114828889B (zh) 2019-12-06 2025-02-14 马瑞纳斯制药公司 用于治疗结节性硬化症的加奈索酮
EP4125921A1 (en) * 2020-03-25 2023-02-08 Sage Therapeutics, Inc. Use of agents for treatment of respiratory conditions
WO2022020363A1 (en) * 2020-07-20 2022-01-27 Sage Therapeutics, Inc. Formulations of 19-nor c3,3- disubstituted c21-n-pyrazolyl steroid and methods of use thereof
CA3206537A1 (en) * 2021-01-28 2022-08-04 Sage Therapeutics, Inc. Use of neuroactive steroids for treatment of sexual dysfunction
BR112023018607A2 (pt) 2021-03-17 2023-10-24 Sage Therapeutics Inc Esteroide de c21-n-pirazolil 19-nor c3,3-dissubstituído para o tratamento de transtorno depressivo maior
US20240216396A1 (en) 2021-04-29 2024-07-04 Sage Therapeutics, Inc. Neuroactive steroid for use in treating major depressive disorder and postpartum depression in a lactating female
AU2022266680A1 (en) 2021-04-29 2023-11-02 Sage Therapeutics, Inc. 19-nor c3,3-disubstituted c21 -n-pyrazolyl steroid for use in treating major depressive disorder and postpartum depression
TW202341995A (zh) 2022-02-16 2023-11-01 美商賽吉醫療公司 用於治療cns相關病症之神經活性類固醇
WO2023163879A1 (en) 2022-02-28 2023-08-31 Sage Therapeutics, Inc. Neuroactive steroids for treatment of gastrointestinal diseases or conditions
IL320996A (en) 2022-11-21 2025-07-01 Sage Therapeutics Inc Negative NMDA modulator compounds and methods of using them
EP4680616A1 (en) 2023-03-14 2026-01-21 Curia Spain, S.A.U. Process and intermediates for the preparation of 3alpha-hydroxy-3beta-alkyl steroids
WO2024230797A1 (zh) 2023-05-11 2024-11-14 上海枢境生物科技有限公司 甾体类化合物、制备方法及其用途

Family Cites Families (162)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2856415A (en) 1957-11-13 1958-10-14 Searle & Co 3,19-dihydroxy-5-androstene derivatives
FR1380417A (fr) 1962-05-15 1964-12-04 Roussel Uclaf Nouveaux androstanyl-pyrazoles et procédé de préparation
NL297205A (enExample) * 1962-08-28
US3206459A (en) 1962-10-19 1965-09-14 Syntex Corp 10alpha-pregnan-19-ol derivatives
US3169134A (en) 1963-03-21 1965-02-09 Searle & Co 2, 3-oxygenated-17alpha-methyl-5alpha-androstan-17beta-ols
US3511860A (en) * 1966-09-26 1970-05-12 Syntex Corp Synthesis of 19-nor and ring a aromatic steroids and intermediates therefor
NL6801449A (enExample) * 1968-02-01 1969-08-05
BE754111A (fr) 1969-07-29 1971-01-29 Upjohn Co Nouveaux 7alpha- et 7beta-methyl-3alpha,5alpha- cycloandrostanes et composes analogues 19-nor et leur procede de preparation
GB1434919A (en) 1972-06-15 1976-05-12 Glaxo Lab Ltd 3alpha-hydroxy androstanes
US3943124A (en) 1970-12-17 1976-03-09 Gordon Hanley Phillipps Chemical compounds
GB1380246A (en) 1970-12-17 1975-01-08 Glaxo Lab Ltd 3alpha-hydroxy-androstanes and esters thereof
GB1430942A (en) 1972-05-05 1976-04-07 Glaxo Lab Ltd 21-substituted 3alpha-hydroxy pregnanes
US3983111A (en) 1972-05-05 1976-09-28 Glaxo Laboratories Limited Steroidal anaesthetics of the pregnane and 19-norpregnane series
GB1436324A (en) 1972-05-12 1976-05-19 Glaxo Lab Ltd Anaesthetic 3alpha-hydroxy pregnanes
DK134348C (da) 1973-11-30 1977-03-21 Schering Ag Analogifremgangsmade til fremstilling af d-homo-20-ketopregnaner
US4071625A (en) 1974-05-13 1978-01-31 Richardson-Merrell Inc. 19-Oxygenated-5α-androstanes for the enhancement of libido
DE2438020A1 (de) 1974-08-05 1976-02-26 Schering Ag 18-methyl-19-nor-20-keto-pregnane und verfahren zu ihrer herstellung
IL48628A0 (en) 1974-12-23 1976-02-29 Schering Ag D-homo-20-keto-pregnanes and process for their manufactur
DE2526373C2 (de) 1975-06-11 1983-11-10 Schering AG, 1000 Berlin und 4709 Bergkamen Verfahren zur Herstellung von Δ↑9↑↑(↑↑1↑↑1↑↑)↑-5α-20-Ketosteroiden
US4192871A (en) 1976-01-06 1980-03-11 Glaxo Laboratories Limited Chemical compounds
GB1570394A (en) 1976-01-06 1980-07-02 Glaxo Lab Ltd 11-acyloxy-3-hydroxy steroids
GB1581234A (en) 1976-04-05 1980-12-10 Glaxo Operations Ltd 11a - amino - 3a - hydroxysteroids
DE2632677A1 (de) 1976-07-16 1978-01-26 Schering Ag Verfahren zur herstellung von androstan-17-on-derivaten und deren verwendung
GB1581235A (en) 1977-04-04 1980-12-10 Glaxo Operations Ltd 11a-amino-3a-hydroxy-steroids
US4389345A (en) 1981-10-09 1983-06-21 G.D. Searle & Co. 3-Oxoestra-17-acetonitrile and unsaturated analogs
US4495102A (en) 1982-09-03 1985-01-22 G. D. Searle & Co. Aminoalkyl steroids
US5319115A (en) 1987-08-25 1994-06-07 Cocensys Inc. Method for making 3α-hydroxy, 3β-substituted-pregnanes
US5120723A (en) 1987-08-25 1992-06-09 University Of Southern California Method, compositions, and compounds for modulating brain excitability
US5232917A (en) 1987-08-25 1993-08-03 University Of Southern California Methods, compositions, and compounds for allosteric modulation of the GABA receptor by members of the androstane and pregnane series
US5376645A (en) 1990-01-23 1994-12-27 University Of Kansas Derivatives of cyclodextrins exhibiting enhanced aqueous solubility and the use thereof
CA2118938A1 (en) 1991-09-13 1993-04-01 Kelvin W. Gee Novel gabaa receptor with steroid binding sites
DE4232681C2 (de) 1992-09-29 1994-11-24 Sigma Tau Ind Farmaceuti 17-Phenyl- und 17-Furyl-14beta,5alpha-androstan- und androsten- Derivate, Verfahren zu deren Herstellung und diese enthaltende pharmazeutische Zusammensetzung
DE69435286D1 (de) 1993-05-24 2010-05-20 Purdue Pharma Ltd Verfahren und zusammensetzungen zum hervorrufen von schlaf
EP0656365B1 (en) 1993-12-02 1997-04-09 Akzo Nobel N.V. Substituted 2beta-morpholinoandrostane derivatives
CZ300694A3 (en) 1993-12-02 1996-05-15 Akzo Nobel Nv Substituted 2beta-morpholinandrostane derivatives, process of their preparation, their use for preparing pharmaceutical preparations and pharmaceutical compositions containing thereof
US5567830A (en) 1994-02-14 1996-10-22 Cocensys, Inc. Process for synthesis of acetylenic carbinols
US5939545A (en) 1994-02-14 1999-08-17 Cocensys, Inc. Method, compositions, and compounds for allosteric modulation of the gaba receptor by members of the androstane and pregnane series
EP0752860B1 (en) * 1994-02-14 2000-08-23 Euro-Celtique S.A. Androstanes and pregnanes for allosteric modulation of gaba receptor
WO1996003421A1 (en) 1994-07-21 1996-02-08 Pharmacia & Upjohn Company Neurologically active aminosteroids
US5792757A (en) * 1994-08-04 1998-08-11 Pherin Pharmaceuticals 19-nor-pregnane steroids as neurochemical initiators of change in human hypothalamic function
AP653A (en) 1994-11-23 1998-07-21 Cocensys Inc Androstane and pregnane series for allosteric modulations of gaba receptor.
US5925630A (en) 1995-06-06 1999-07-20 Cocensys, Inc. Neuroactive steroids of the androstane and pregnane series
AU3967297A (en) * 1996-08-01 1998-02-25 Cocensys, Inc. Use of gaba and nmda receptor ligands for the treatment of migraine headache
US5994334A (en) 1997-02-05 1999-11-30 University Of Maryland Androgen synthesis inhibitors
US5935545A (en) 1997-07-11 1999-08-10 E. I. Du Pont De Nemours And Company Process for producing an aqueous solution comprising ferric chloride
IL146230A0 (en) * 1999-04-29 2002-07-25 Purdue Pharma Ltd 3α-HYDROXY-3β-METHOXYMETHYL-SUBSTITUTED STEROIDS AND PHARMACEUTICAL COMPOSITIONS CONTAINING THE SAME
US7018406B2 (en) 1999-11-17 2006-03-28 Corevalve Sa Prosthetic valve for transluminal delivery
US6717002B2 (en) 2000-02-18 2004-04-06 Taiho Pharmaceutical Co., Ltd. Method of producing steroid derivatives
US6855836B2 (en) 2000-10-26 2005-02-15 Jenapharm Gmbh & Co. Kg 17-Methylene steroids, process for their production and pharmaceutical compositions that contain these compounds
US6844456B2 (en) 2000-11-03 2005-01-18 Washington University Modified, hydroxy-substituted aromatic structures having cytoprotective activity
GR1003861B (el) 2000-12-29 2002-04-11 Νεα νευροστεροειδη που αλληλεπιδρουν με τον υποδοχεα gabaa.
JP4719144B2 (ja) 2003-03-24 2011-07-06 ステリックス リミテッド ステロイドスルファターゼのインヒビターとしてのエストロゲン誘導体
EP1626980A4 (en) 2003-05-29 2007-07-04 Univ Washington NEUROACTIVE 13,24-CYCLO-18,21-DINORCHOLANES AND STRUCTURELY RELATED PENTACYCLIC STEROIDS
US20070099880A1 (en) 2003-11-24 2007-05-03 Blizzard Timothy A Estrogen receptor modulators
WO2005105822A2 (en) 2004-04-23 2005-11-10 Euro-Celtique S.A. 3-alpha-hydroxy 21-n- heteroaryl-pregnane derivatives for modulation of brain excitability and a process for the production thereof
AU2005282727A1 (en) * 2004-09-03 2006-03-16 Celgene Corporation Substituted heterocyclic compounds and uses thereof
WO2006037016A2 (en) 2004-09-27 2006-04-06 The Regents Of The University Of California Novel therapy for treatment of chronic degenerative brain diseases and nervous system injury
AU2005330504B2 (en) 2004-09-29 2010-10-28 Harbor Biosciences, Inc. Steroid analogs and characterization and treatment methods
US8030298B2 (en) * 2005-05-26 2011-10-04 Abbott Products Gmbh 17β-HSD1 and STS inhibitors
SI2168585T1 (sl) 2005-06-09 2012-04-30 Euro Celtique Sa Farmacevtski sestavki nevroaktivnega steroida in njihove uporabe
CN100362013C (zh) * 2006-03-16 2008-01-16 中国科学院上海有机化学研究所 一类c22-羰基甾体化合物、合成方法及其用途
KR20090006148A (ko) * 2006-04-05 2009-01-14 와이어쓰 5-히드록시트립타민-6 리간드로서의 설포닐-3-헤테로시클릴인다졸 유도체
CN101506221B (zh) * 2006-09-19 2012-09-12 索尔瓦药物有限公司 雌三烯衍生物及其作为17β-羟基类固醇脱氢酶抑制剂的用途
US20090203658A1 (en) 2007-01-08 2009-08-13 Duke University Neuroactive steroid compositions and methods of use therefor
DE102007027636A1 (de) 2007-06-12 2008-12-18 Bayer Schering Pharma Aktiengesellschaft 17ß-Cyano-18a-homo-19-nor-androst-4-en-Derivat, dessen Verwendung und das Derivat enthaltende Arzneimittel
EP2155204B1 (en) 2007-06-15 2016-08-17 Research Triangle Institute Androstane and pregnane steroids with potent allosteric gaba receptor chloride ionophore modulating properties
GB0711948D0 (en) 2007-06-20 2007-08-01 Bionature E A Ltd Neurosteriod compounds
CN101412742B (zh) 2007-10-19 2013-07-31 天津金耀集团有限公司 一种抑制血管新生的硝酸酯药物
KR100958286B1 (ko) * 2007-11-15 2010-05-19 한국과학기술원 ａ１Ｇ Ｔ―타입 칼슘 채널을 억제하여 본태성 진전증을예방 및 치료하는 방법
US20090264443A1 (en) 2008-04-18 2009-10-22 David Helton Treatment of organophosphate exposure with tetrahydroindolone arylpiperazine compounds
CN101624414B (zh) 2008-07-07 2013-02-13 天津金耀集团有限公司 一种抑制血管新生的硝酸酯药物
CZ2008434A3 (cs) 2008-07-10 2009-12-09 Ústav organické chemie a biochemie Akademie ved CR, v. v. i. Pregnanové anionické slouceniny, zpusob jejich výroby a jejich použití
US20100120733A1 (en) 2008-11-07 2010-05-13 Auspex Pharmaceuticals, Inc. Steroid modulators of glucocorticoid receptor
US20110152840A1 (en) 2009-12-23 2011-06-23 Drugtech Corporation Methods for reducing the occurrence of preterm delivery and other pregnancy-related conditions
AU2011284606A1 (en) 2010-07-30 2013-03-14 Pharmacellion Ltd Compounds and methods for treating neoplasia
CN103347525A (zh) 2010-12-15 2013-10-09 哈博生物科学公司 制备3α-氧取代的甾族化合物的方法及化合物
CZ201181A3 (cs) 2011-02-15 2012-09-12 Ústav organické chemie a biochemie Akademie ved CR, v.v.i. Deriváty pregnanolonu substituované v poloze 3alfa kationickou skupinou, zpusob jejich výroby, jejich použití a prostredek je obsahující
US9457033B2 (en) 2011-02-15 2016-10-04 Socpra Sciences Et Genie, S.E.C. Steroid alkaloids and uses thereof as antimicrobial agents against electron transport-deficient microbes and as potentiators for antimicrobial agents against pathogenic bacteria
US9388210B2 (en) 2011-02-25 2016-07-12 Washington University Neuroactive 17(20)-Z-vinylcyano-substituted steroids, prodrugs thereof, and methods of treatment using same
JP5265816B2 (ja) 2011-03-23 2013-08-14 悦朗 伊藤 タンパク質および核酸の超高感度測定法およびキット、並びに新規な酵素基質
JP2014521662A (ja) 2011-07-29 2014-08-28 ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア ＧＡＢＡＡ受容体のモジュレーターとしての新規な１７β−ヘテロアリール置換ステロイド
EP4245369A3 (en) * 2011-09-08 2023-11-22 Sage Therapeutics, Inc. Neuroactive steroids, compositions, and uses thereof
AU2012323888A1 (en) 2011-10-14 2014-05-29 Sage Therapeutics, Inc. 3,3 disubstituted 19-nor pregnane compounds, compositions, and uses thereof
NZ627781A (en) 2012-01-23 2016-10-28 Sage Therapeutics Inc Neuroactive steroid formulations and methods of treating cns disorders
US20150175651A1 (en) 2012-06-15 2015-06-25 Sage Therapeutics, Inc. Neuroactive steroids, compositions, and uses thereof
SG10201607230SA (en) 2012-06-19 2016-10-28 Intercept Pharmaceuticals Inc Preparation, Uses And Solid Forms Of Obeticholic Acid
US20140050789A1 (en) 2012-08-13 2014-02-20 The Regents Of The University Of California Mitigation of epileptic seizures by combination therapy using benzodiazepines and neurosteroids
SG10201608148TA (en) 2012-08-21 2016-11-29 Sage Therapeutics Inc Methods Of Treating Epilepsy Or Status Epilepticus
WO2014058736A1 (en) 2012-10-08 2014-04-17 Washington University Neuroactive 19-alkoxy-17(20)-z-vinylcyano-substituted steroids, prodrugs thereof, and methods of treatment using same
EP2916846B1 (en) 2012-11-09 2025-09-17 Drawbridge Pharmaceuticals Pty Ltd Neuroactive steroids and their use to facilitate neuroprotection
ES2973320T3 (es) 2012-11-30 2024-06-19 Univ California Alopregnanolona para tratar, reducir o mitigar los síntomas de la depresión posparto
EP3392260B1 (en) 2012-12-18 2022-09-21 Washington University Neuroactive 19-alkoxy-17-substituted steroids, useful in methods of treatment
US8939545B2 (en) 2012-12-20 2015-01-27 Eastman Kodak Company Inkjet printing with managed airflow for condensation control
CA2831054C (en) 2013-01-09 2016-08-30 Sapna Life Sciences Corp. Formulations, and methods for their use in treatment of neuropathology and neurodegeneration as a result of traumatic injury
WO2014108808A2 (en) 2013-01-09 2014-07-17 Henry James Lorne Pharmaceutical formulations for the treatment and prevention of trauma-induced neuropathology and neurodegeneration
GB201302368D0 (en) 2013-02-11 2013-03-27 Univ Bath Compound
US9512170B2 (en) 2013-03-01 2016-12-06 Washington University Neuroactive 13, 17-substituted steroids as modulators for GABA type-A receptors
US9562026B2 (en) 2013-03-14 2017-02-07 Washington University Neuroactive substituted cyclopent[a]anthracenes as modulators for GABA type-A receptors
PL3498725T3 (pl) 2013-04-17 2021-11-08 Sage Therapeutics, Inc. 19-Nor C3,3-dipodstawiony C21-N-pirazolilo-steroid do zastosowania w terapii
US9725481B2 (en) 2013-04-17 2017-08-08 Sage Therapeutics, Inc. 19-nor C3, 3-disubstituted C21-C-bound heteroaryl steroids and methods of use thereof
US20160068563A1 (en) 2013-04-17 2016-03-10 Boyd L. Harrison 19-nor neuroactive steroids and methods of use thereof
DK2986624T3 (da) 2013-04-17 2020-06-29 Sage Therapeutics Inc Neuroaktive 19-nor-steroider til terapeutisk anvendelse
EP3021852B1 (en) 2013-07-19 2021-01-27 Sage Therapeutics, Inc. Neuroactive steroids, compositions, and uses thereof
PT3488852T (pt) 2013-08-23 2021-02-03 Sage Therapeutics Inc Esteroides neuroativos, composições e seus usos
CA2949720C (en) 2014-05-29 2025-11-18 Sage Therapeutics, Inc. NEUROACTIVE STEROIDS, THEIR COMPOSITION AND USES
US10246482B2 (en) 2014-06-18 2019-04-02 Sage Therapeutics, Inc. Neuroactive steroids, compositions, and uses thereof
EP3188734A4 (en) 2014-09-02 2018-01-10 The Texas A&M University System Method of treating organophosphate intoxication
JOP20200195A1 (ar) 2014-09-08 2017-06-16 Sage Therapeutics Inc سترويدات وتركيبات نشطة عصبياً، واستخداماتها
ES2808855T3 (es) 2014-10-16 2021-03-02 Sage Therapeutics Inc Composiciones y métodos para tratar trastornos del SNC
PE20170925A1 (es) 2014-10-16 2017-07-13 Sage Therapeutics Inc Composiciones y metodos para el tratamiento de trastornos del snc
US10774108B2 (en) 2014-11-27 2020-09-15 Sage Therapeutics, Inc. Compositions and methods for treating CNS disorders
RS61530B1 (sr) 2015-01-26 2021-04-29 Sage Therapeutics Inc Kompozicije i postupci za lečenje poremećaja cns
CN105985396A (zh) 2015-02-16 2016-10-05 苏州泽璟生物制药有限公司 氘代鹅去氧胆酸衍生物以及包含该化合物的药物组合物
WO2016134301A2 (en) 2015-02-20 2016-08-25 Sage Therapeutics, Inc. Neuroactive steroids, compositions, and uses thereof
WO2016164763A1 (en) 2015-04-10 2016-10-13 Sage Therapeutics, Inc. Compositions and methods for treating cns disorders
MA45276A (fr) 2015-06-18 2018-04-25 Sage Therapeutics Inc Solutions de stéroïdes neuroactifs et leurs méthodes d'utilisation
UY36741A (es) 2015-06-21 2016-12-30 Prevacus Inc Compuesto de esteroide c-20, sus composiciones y usos para tratar la lesión cerebral traumática (tbi), que incluye las conmociones cerebrales
CN108350021A (zh) 2015-09-08 2018-07-31 视点医疗公司 用于治疗眼科疾病的化合物和制剂
WO2017066626A1 (en) 2015-10-16 2017-04-20 Marinus Pharmaceuticals, Inc. Injectable neurosteroid formulations containing nanoparticles
EP3377070A4 (en) 2015-11-20 2019-07-10 Sage Therapeutics, Inc. COMPOUNDS AND METHOD FOR THEIR USE
TW202400182A (zh) 2016-03-08 2024-01-01 美商賽吉醫療公司 神經活性類固醇，其組合物及用途
US10226550B2 (en) 2016-03-11 2019-03-12 Brigham Young University Cationic steroidal antimicrobial compositions for the treatment of dermal tissue
CA3279953A1 (en) 2016-07-11 2025-11-29 Sage Therapeutics, Inc. C7, c12, and c16 substituted neuroactive steroids and their methods of use
EP4302764A3 (en) 2016-07-11 2024-06-26 Sage Therapeutics, Inc. C17, c20, and c21 substituted neuroactive steroids and their methods of use
BR112019003637A2 (pt) 2016-08-23 2019-08-06 Sage Therapeutics Inc um esteróide 19-nor c3,3-dissubstituído c21-n-pirazolil cristalino
US10391105B2 (en) 2016-09-09 2019-08-27 Marinus Pharmaceuticals Inc. Methods of treating certain depressive disorders and delirium tremens
CN108727453A (zh) 2017-04-20 2018-11-02 华东理工大学 新型pd-1抑制剂及其应用
WO2019018119A1 (en) 2017-07-18 2019-01-24 Pairnomix, Llc METHODS FOR TREATING EPILEPSY AND DISORDERS ASSOCIATED WITH KCNTI
MX2020001732A (es) 2017-08-31 2020-03-20 Takeda Pharmaceuticals Co Tratamiento de las afecciones del sistema nervioso central.
IL303250A (en) 2017-09-07 2023-07-01 Sage Therapeutics Inc Neuroactive steroids and their methods of use
WO2019051477A1 (en) 2017-09-11 2019-03-14 Sage Therapeutics, Inc. METHODS OF TREATING EPILEPSY OR EPILEPTIC MALE CONDITION
US20220110949A1 (en) 2017-09-14 2022-04-14 Sage Therapeutics, Inc. A 19-nor c3,3-disubstituted c21-n-pyrazolyl steroid and methods of use thereof
US20190160078A1 (en) 2017-11-10 2019-05-30 Marinus Pharmaceuticals, Inc. Ganaxolone for use in treating genetic epileptic disorders
JP2021505608A (ja) 2017-12-08 2021-02-18 セージ セラピューティクス， インコーポレイテッド ＣＮＳ障害を処置するためのジュウテリウム化された２１−［４−シアノ−ピラゾール−１−イル］−１９−ノル−プレガン−３．α−オール−２０−オン誘導体
AU2018392093B2 (en) 2017-12-22 2024-02-01 Sage Therapeutics, Inc. Compositions and methods for treating CNS disorders
IL310454A (en) 2017-12-22 2024-03-01 Sage Therapeutics Inc Compositions and methods for treating cns disorders
EP3737687B1 (en) 2018-01-12 2025-10-22 Sage Therapeutics, Inc. Aza-, oxa and thia-pregnan-20-one-3.alpha.-ol compounds for use in treating cns disorders
UY38213A (es) 2018-05-04 2019-10-31 Acerus Pharmaceuticals Corp Derivados de neuroesteroides y usos de estos
CA3103421A1 (en) 2018-06-12 2019-12-19 Sage Therapeutics, Inc. A 19-nor c3,3-disubstituted c21 -n-pyrazolyl steroid and methods of use thereof
CA3115805A1 (en) 2018-10-12 2020-04-16 Sage Therapeutics, Inc. Neuroactive steroids substituted in position 10 with a cyclic group for use in the treatment of cns disorders
BR112021007401A2 (pt) 2018-10-19 2021-08-03 Sage Therapeutics, Inc. esteroides neuroativos insaturados 9(11) e seus métodos de uso
KR102892974B1 (ko) 2018-12-05 2025-11-28 세이지 테라퓨틱스, 인크. 신경활성 스테로이드 및 이의 사용 방법
TWI892697B (zh) 2018-12-21 2025-08-01 美商賽吉醫療公司 神經活性類固醇及其組合物
TWI855081B (zh) 2019-05-24 2024-09-11 美商賽吉醫療公司 化合物、組合物及使用方法
BR112021024033A2 (pt) 2019-05-31 2022-02-08 Sage Therapeutics Inc Esteroides neuroativos e suas composições
TWI896548B (zh) 2019-06-27 2025-09-11 美商賽吉醫療公司 用於治療cns病症之組合物及方法
EP3990467A1 (en) 2019-06-27 2022-05-04 Sage Therapeutics, Inc. Compositions and methods for treating cns disorders
TWI896547B (zh) 2019-06-27 2025-09-11 美商賽吉醫療公司 用於治療cns病症之組合物及方法
AU2020395246A1 (en) 2019-12-05 2022-06-16 Sage Therapeutics, Inc. A 19-nor C3,3-disubstituted C21-N-pyrazolyl steroid and methods of use thereof
TW202143976A (zh) 2020-03-18 2021-12-01 美商賽吉醫療公司 神經活性類固醇及其使用方法
EP4125921A1 (en) 2020-03-25 2023-02-08 Sage Therapeutics, Inc. Use of agents for treatment of respiratory conditions
IL299176A (en) 2020-06-24 2023-02-01 Sage Therapeutics Inc Neuroactive steroids converted to 3.alpha.-hydroxy, 17.beta.-C-(O)-N-aryl and their compounds
WO2022020363A1 (en) 2020-07-20 2022-01-27 Sage Therapeutics, Inc. Formulations of 19-nor c3,3- disubstituted c21-n-pyrazolyl steroid and methods of use thereof
JP2023550653A (ja) 2020-11-25 2023-12-04 セージ セラピューティクス， インコーポレイテッド Ｃｎｓの障害を治療するための組成物及び方法
CA3206537A1 (en) 2021-01-28 2022-08-04 Sage Therapeutics, Inc. Use of neuroactive steroids for treatment of sexual dysfunction
WO2022177718A1 (en) 2021-02-18 2022-08-25 Sage Therapeutics, Inc. Use of neuroactive steroid for treatment of sexual dysfunction
BR112023018607A2 (pt) 2021-03-17 2023-10-24 Sage Therapeutics Inc Esteroide de c21-n-pirazolil 19-nor c3,3-dissubstituído para o tratamento de transtorno depressivo maior
EP4322960A1 (en) 2021-04-12 2024-02-21 Sage Therapeutics, Inc. Treatment of essential tremor
AU2022266680A1 (en) 2021-04-29 2023-11-02 Sage Therapeutics, Inc. 19-nor c3,3-disubstituted c21 -n-pyrazolyl steroid for use in treating major depressive disorder and postpartum depression
US20240216396A1 (en) 2021-04-29 2024-07-04 Sage Therapeutics, Inc. Neuroactive steroid for use in treating major depressive disorder and postpartum depression in a lactating female
TW202341995A (zh) 2022-02-16 2023-11-01 美商賽吉醫療公司 用於治療cns相關病症之神經活性類固醇
WO2023163879A1 (en) 2022-02-28 2023-08-31 Sage Therapeutics, Inc. Neuroactive steroids for treatment of gastrointestinal diseases or conditions

Also Published As

Publication number Publication date
AU2018278844A1 (en) 2019-01-03
RU2675855C2 (ru) 2018-12-25
EP2986623A1 (en) 2016-02-24
IL310348A (en) 2024-03-01
MX2015014600A (es) 2016-03-03
LT3498725T (lt) 2021-09-27
PT3498725T (pt) 2021-09-09
JP2018199716A (ja) 2018-12-20
CN113527400A (zh) 2021-10-22
HK1224301A1 (en) 2017-08-18
RU2018143835A (ru) 2019-01-16
PL3498725T3 (pl) 2021-11-08
HRP20190232T1 (hr) 2019-03-22
EP3909966B1 (en) 2025-07-09
CN113527400B (zh) 2024-06-28
HUE041369T2 (hu) 2019-05-28
BR112015026380A8 (pt) 2019-12-31
IL286794B1 (en) 2024-02-01
CN108440633A (zh) 2018-08-24
KR20220062690A (ko) 2022-05-17
SI3498725T1 (sl) 2021-11-30
US20250319106A1 (en) 2025-10-16
EP3498725B1 (en) 2021-06-09
EP4640277A2 (en) 2025-10-29
AU2014256229B2 (en) 2018-10-04
DK3909966T3 (da) 2025-09-29
BR112015026380A2 (pt) 2017-07-25
SI2986623T1 (sl) 2019-03-29
US20220110950A1 (en) 2022-04-14
KR102239541B1 (ko) 2021-04-14
CA2909545A1 (en) 2014-10-23
CY1125416T1 (el) 2023-03-24
EP2986623A4 (en) 2016-09-28
HRP20211314T1 (hr) 2021-11-26
EP4640277A3 (en) 2025-12-31
US9512165B2 (en) 2016-12-06
RS58297B1 (sr) 2019-03-29
CN108440633B (zh) 2021-07-13
JP2021001220A (ja) 2021-01-07
JP2016517851A (ja) 2016-06-20
EP3909966A1 (en) 2021-11-17
RU2015149008A (ru) 2017-05-22
JP7085601B2 (ja) 2022-06-16
KR20230172622A (ko) 2023-12-22
EP2986623B1 (en) 2018-11-07
AU2014256229A1 (en) 2015-11-05
JP2019001807A (ja) 2019-01-10
AU2014256229A9 (en) 2016-03-17
JP2023154010A (ja) 2023-10-18
JP7668850B2 (ja) 2025-04-25
US20170246191A1 (en) 2017-08-31
SG11201508550XA (en) 2015-11-27
SG10201802389SA (en) 2018-04-27
KR102614507B1 (ko) 2023-12-19
KR102396328B1 (ko) 2022-05-10
ZA201507740B (en) 2017-09-27
EP3498725A1 (en) 2019-06-19
CN105339381A (zh) 2016-02-17
KR20210041121A (ko) 2021-04-14
CN118754924A (zh) 2024-10-11
DK2986623T3 (en) 2019-03-04
AU2018278844B2 (en) 2020-07-16
WO2014169833A9 (en) 2016-03-03
IL286794A (en) 2021-10-31
CY1121228T1 (el) 2020-05-29
MX395023B (es) 2025-03-24
IL278487B (en) 2021-10-31
US20180311262A1 (en) 2018-11-01
HUE055554T2 (hu) 2021-12-28
ES3044385T3 (en) 2025-11-26
JP2022058758A (ja) 2022-04-12
US11241446B2 (en) 2022-02-08
US20200155576A1 (en) 2020-05-21
AU2020256400A1 (en) 2020-11-12
PL2986623T3 (pl) 2019-04-30
RS62312B1 (sr) 2021-09-30
AU2020256400B2 (en) 2022-04-28
JP6470258B2 (ja) 2019-02-13
US20160108080A1 (en) 2016-04-21
NZ713303A (en) 2021-03-26
ES2886182T3 (es) 2021-12-16
MX2022007490A (es) 2022-07-05
US10172871B2 (en) 2019-01-08
JP7527318B2 (ja) 2024-08-02
SMT201900066T1 (it) 2019-02-28
SMT202100509T1 (it) 2021-11-12
PT2986623T (pt) 2019-02-06
LT2986623T (lt) 2019-02-25
WO2014169833A1 (en) 2014-10-23
CN105339381B (zh) 2018-04-27
JP2025060975A (ja) 2025-04-10
AU2022205157B2 (en) 2024-09-19
DK3498725T3 (da) 2021-08-30
IL286794B2 (en) 2024-06-01
MX362543B (es) 2019-01-24
US12201640B2 (en) 2025-01-21
ES2709434T3 (es) 2019-04-16
US10342810B2 (en) 2019-07-09
AU2024278325A1 (en) 2025-01-09
JP6710730B2 (ja) 2020-06-17
KR20150143690A (ko) 2015-12-23
AU2022205157A1 (en) 2022-07-28
JP6784735B2 (ja) 2020-11-11
IL242089B (en) 2020-11-30

Similar Documents

Publication Publication Date Title
TR201901745T4 (tr) 19-nor C3,3-disübstitüe edilmiş C21- n-pirazolil steroidleri ve bunların kullanım yöntemleri.
US11344563B2 (en) 19-nor C3, 3-disubstituted C21-C-bound heteroaryl steroids and methods of use thereof
AU2017203495B2 (en) 19-Nor Neuroactive Steroids And Methods Of Use Thereof
JP2025184962A (ja) オキシステロールおよびその使用方法
RU2812930C2 (ru) 19-нор c3,3-дизамещенные c21-n-пиразолильные стероиды и способы их применения
HK40062768A (en) 19-nor c3,3-disubstituted c21-n-pyrazolyl steroid for use in therapy
HK40010209A (en) 19-nor c3,3-disubstituted c21-n-pyrazolyl steroid for use in therapy
NZ752696B2 (en) 19-nor C3,3-disubstituted C21-N-pyrazolyl steroids and methods of use thereof
NZ752693B2 (en) 19-nor C3,3-disubstituted C21-N-pyrazolyl steroids and methods of use thereof
NZ752696A (en) 19-nor C3,3-disubstituted C21-N-pyrazolyl steroids and methods of use thereof
HK1220979B (en) 19-nor neuroactive steroids and methods of treatment